{"id":"NCT02141399","sponsor":"Alkermes, Inc.","briefTitle":"A Long-Term Safety Study of ALKS 5461","officialTitle":"A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2017-11-20","completion":"2017-11-20","firstPosted":"2014-05-19","resultsPosted":"2018-12-14","lastUpdate":"2018-12-14"},"enrollment":1485,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"ALKS 5461","otherNames":[]}],"arms":[{"label":"ALKS 5461","type":"EXPERIMENTAL"}],"summary":"This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.","primaryOutcome":{"measure":"Incidence of Adverse Events (AEs)","timeFrame":"Up to 56 weeks","effectByArm":[{"arm":"ALKS 5461","deltaMin":1124,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":158,"countries":["United States","Australia","Bulgaria","Canada","Germany","Hungary","Poland","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":1485},"commonTop":["Nausea","Headache","Constipation","Dizziness","Somnolence"]}}